Compare SPSC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | TYRA |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | 2021 |
| Metric | SPSC | TYRA |
|---|---|---|
| Price | $55.36 | $35.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $96.80 | $47.50 |
| AVG Volume (30 Days) | 504.1K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $7.37 | N/A |
| P/E Ratio | $22.42 | ★ N/A |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $50.55 | $8.75 |
| 52 Week High | $153.16 | $40.65 |
| Indicator | SPSC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 45.54 |
| Support Level | $52.05 | $33.81 |
| Resistance Level | $59.69 | $39.90 |
| Average True Range (ATR) | 2.30 | 1.97 |
| MACD | 0.31 | -0.11 |
| Stochastic Oscillator | 56.51 | 29.08 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. The company has one operating segment Supply Chain Management Solutions, that derives revenues from customers by providing access to cloud-based supply chain management services, primarily under subscription-based service arrangements.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.